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City, TaiwanReceived 16 June 2016; accepted 19 August 2016Although postinfluenza invasive pulmonary aspergillosis
(IPA) is not uncommon, only two fatal cases to date have
been reported in Taiwan.1e3 This suggests that there is a
need to raise clinical awareness for better management of
postinfluenza IPA in Taiwan.
A 71-year-old man with chronic obstructive pulmonary
disease (COPD) and urinary bladder carcinoma had acute
dyspnea for 2 days. He had undergone transurethral
resection of the bladder tumor (T1N0M0) and had just
received local chemotherapy 3 days prior to his admis-
sion. High fever (39.6C) was noted. The chest X-ray
(CXR) scan showed bilateral lung infiltrations (Figure 1A).
The rapid influenza diagnostic test in the nasopharyngeal
swab revealed a positive antigen for influenza A virus. He
was intubated for acute respiratory failure and was
admitted to the intensive care unit on March 30, 2015.
His laboratory data showed the following: white cell
count of 8800/mL; C-reactive protein, 36.60 mg/L; and
procalcitonin, 0.23 ng/mL. A throat swab polymerase
chain reaction (PCR) for influenza revealed influenza
A(H3N2) virus. Oseltamivir was administered to the
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bacter baumanii 10 days later. Piperacillin and then
ceftazidime plus colistin were administered. However,
PCR for influenza A(H3N2) remained positive on April 9.
The CXR pattern progressed to multiple nodules and
patch consolidations in both lungs (Figures 1B and 1C). A
second course of oseltamivir was given. The Aspergillus
galactomannan (GM) antigen index in blood samples ob-
tained on April 10 was 0.66 (positive, 0.5). Meanwhile,
two cultures of endobronchial sputum on April 13 and
April 14 as well as one bronchoalveolar lavage culture on
April 16 all yielded Aspergillus species. Voriconazole was
initiated on April 15. Nonetheless, cavitating pneumonia
occurred (Figure 1D). The follow-up PCR for influenza A
was still positive on May 4. A third course of oseltamivir
was then given. However, pulmonary lesions deteriorated
with complication of pyopneumothorax (neutrophil,
66,346/mL) in the left hemithorax (Figure 1E), and a chest
tube was inserted. The pleural fluid cultures showed no
growth. Although voriconazole had been continued for 4
weeks, pneumonia and cavities were not resolved
(Figure 1F). As septic shock persisted, the patient passed
away on May 12, 2015.
IPA occurs predominantly in severely immunocompro-
mised hosts like prolonged neutropenia and allogeneic
stem cell transplant; nonetheless, additional patients are
at risk for IPA, such as patients with COPD, diabetes
mellitus, severe influenza, and critical illness.1,4 Our
patient had several diseases at risk, including bladder
cancer, COPD, severe influenza, and critical illness, which3N2) refractory invasive pulmonary aspergillosis, Journal of the
a.2016.08.005
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Figure 1 Chest X-ray (CXR) series. (AeC) Progressive change of lung infiltrates. (DeF) Cavitary lung lesions. (E) Pyopneumo-
thorax. (F) Post-chest tube insertion status. The arrows denote the characteristic “ball-in-hole” appearance (E and F).
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regulation. Together with pulmonary cavities, positive
serum GM assay, and isolation of Aspergillus from respira-
tory samples, the diagnosis of IPA is convincing. Aspergillus
GM is a major aspergillar exoantigen released during inva-
sive disease, thus indicating a true infection rather than
contamination.5
In conclusion, we report a refractory curse of fatal IPA
after influenza A(H3N2) infection. A delayed diagnosis
and therapy might have contributed to the non-
responsiveness of the disease. However, there is no
consensus on the timely diagnosis and treatment for
postinfluenza IPA. We suggest earlier diagnosis by GM
detection and pre-emptive therapy for IPA prior to
disease progression.
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